Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RESEARCH TOOLSreports
TransCode Therapeutics (RNAZ) Stock Price & Analysis
195 Followers
RNAZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.42 - $166.40
Previous Close$1.78
Volume410.91K
Average Volume (3M)1.26M
Market Cap
$11.66M
Enterprise Value$8.73M
Total Cash (Recent Filing)$3.60M
Total Debt (Recent Filing)$663.29K
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 12, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-205.92
Shares Outstanding6,622,053
10 Day Avg. Volume1,615,604
30 Day Avg. Volume1,258,473
Standard Deviation0.28
R-Squared0.00448
Alpha-0.16
Financial Highlights & Ratios
Price to Book (P/B)2.65
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$3.00Price Target Upside69.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
TransCode Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyPreclinical studies show TTX-MC138 may be effective in reducing metastatic tumor sites, indicating potential for disease improvement.
Market PotentialFDA IND clearance for Phase 1/2 study of TTX-MC138 in advanced solid tumors highlights regulatory progress and a broad potential market.
Safety ProfileTTX-MC138 has been observed to be safe with no adverse events at microdose levels, suggesting a favorable safety profile for patients.
Bears Say
Financial StabilityThe company will need to secure additional funding to sustain operations, indicating potential financial instability.
Listing Status RiskThe threat of de-listing and potential reverse stock split to maintain Nasdaq listing could negatively affect the stock.
Regulatory And Efficacy ChallengesRisks include lower than expected clinical efficacy and regulatory concerns which could impact the stock's performance.
---
Ownership Overview
3.60% Insiders
0.02% Mutual Funds
5.94% Other Institutional Investors
90.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $0.42 and its highest was $166.40 in the past 12 months.
What is TransCode Therapeutics’s market cap?
Currently, no data Available
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Aug 12, 2024 which is in 71 days.
How were TransCode Therapeutics’s earnings last quarter?
Currently, no data Available
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Undervalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate is -$0.58.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 6,570,063 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
---
TransCode Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (69.01% Upside)
$3.00 (69.01% Upside)
Blogger Sentiment
Bullish
RNAZ Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 24.4%
Last 30 Days ▲ 24.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.94%
12-Months-Change
Fundamentals
Return on Equity
-784.63%
Trailing 12-Months
Asset Growth
30.41%
Trailing 12-Months
Company Description
TransCode Therapeutics
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
---
RNAZ Stock 12 Month Forecast
Average Price Target
$3.00
▲(69.01% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Sangamo Biosciences
―
RegenXBio
―
Crispr Therapeutics AG
―
Best Analysts Covering RNAZ
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-45.92%
assigned a buy rating 5 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -45.92% per trade.
---